As lawyers who represent whistleblowers under the False Claims Act, we expect a new era of fraud cases tied to GLP-1 drugs, ...

A groundbreaking initiative from the Trump administration could revolutionize access to costly weight-loss drugs under Medicare and Medicaid. This plan aims to provide millions of Americans suffering ...

Pharma firms are pouncing on opportunity as patents on world’s second-bestselling drug, which goes by brand names Ozempic and ...

The next generation of diabetes and weight loss drugs could come in pill form, deliver even greater weight loss results, and provide more health benefits.

If the plan pans out, it would be an enormous boon to Eli Lilly and Novo Nordisk. Currently, many health insurance plans, as ...

People enrolled in the military health care benefits program Tricare for Life no longer will be eligible for coverage of ...

GLP-1 weight-loss drugs are popular but pricey. New data highlights use by age and gender - and why interest outpaces access for many.

The Centers for Medicare & Medicaid Services (CMS) is developing a pilot program that could change the landscape of obesity ...

For 14 years, Jesse’s mind spiraled. So did his weight. The medications he took for schizophrenia drove his weight up until ...

Novo Nordisk reported second quarter earnings a week after revising its 2025 outlook down on slower GLP-1 sales.

Medicare is expanding its drug price negotiation program to include 15 more medications, including popular drugs like Ozempic.

Novo Nordisk's already depressed share price has fallen again this morning, despite reporting an 18% increase in sales in the ...